When people research peptide bioregulators, they usually start with the better-known names: BPC-157, TB-500, Epitalon. Vesugen tends to come up later, once someone starts digging into the cardiovascular side of the peptide space.
That trajectory makes sense given where Vesugen comes from. It was developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson, part of a decades-long Soviet and later Russian research program into short peptide bioregulators targeting specific organ systems.
Vesugen’s target is the vascular system: specifically the endothelial cells lining blood vessel walls, which play a central role in circulation, vascular tone, and cardiovascular aging.
The research behind it is almost entirely Russian in origin, which has historically limited its visibility in Western scientific and biohacking communities. That is changing as more of the underlying studies become available in translation and as interest in peptide bioregulators grows more broadly.
This article covers what Vesugen is, how it works at a cellular and genetic level, what the research shows across its key applications, how it is dosed, what realistic results look like, and how to contextualize evidence that is real but limited by Western standards.
Vesugen is a synthetic tripeptide bioregulator with the amino acid sequence Lys-Glu-Asp (lysine, glutamic acid, aspartic acid), commonly referred to by its abbreviation KED.
Its molecular formula is C15H26N4O8 with a molecular weight of 390.39 g/mol. It is a linear tripeptide with no secondary or tertiary structure, which gives it excellent stability and facilitates its absorption and intracellular access.
The compound belongs to a family of ultrashort peptide bioregulators developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, a research program that began in the 1970s and 1980s under Soviet military medicine with the goal of developing peptide-based interventions to support health and longevity in soldiers and cosmonauts under extreme conditions.
Over four decades, Khavinson’s group produced a library of organ-specific short peptides, six of which were approved as pharmaceutical drugs in Russia and the CIS, with dozens more registered as dietary supplements.
Vesugen’s specific target is the vascular system, which is why it is classified as a vascular peptide bioregulator. It was designed to support the structural and functional integrity of blood vessel walls, with particular attention to the endothelial cell layer.
Endothelial cells line the inner surface of every blood vessel in the body and regulate vascular tone, permeability, coagulation, and inflammation. Their progressive dysfunction with age is one of the primary drivers of cardiovascular disease.
Vesugen is available in two main forms: a synthesized cytogen version (Cytogens are lab-synthesized analogues of the active peptide sequences) and a natural extract version derived from vascular tissue of young animals (Cytomaxes).
The synthesized form offers more precise and consistent dosing. It is sold under the Vesugen brand name by NPCRIZ, the commercial arm of the St. Petersburg Institute, and by various Western research peptide suppliers as a raw lyophilized powder
Vesugen’s mechanism is more sophisticated than most short peptides in the supplement space are credited with. The initial assumption was that small peptides like KED simply provided amino acid building blocks for tissue repair. The research has revealed something more specific and more interesting.
Ultrashort peptides in the Khavinson family, including Vesugen, have been shown to penetrate cell nuclei and nucleoli, where they interact directly with DNA and histone proteins.
This interaction influences which genes are expressed and at what level, a mechanism that places them in the category of epigenetic regulators rather than simple substrates.
Studies suggest Vesugen binds to promoter regions of target genes, including the Ki-67 proliferation marker gene (MKI67), altering transcriptional activity in a tissue-specific manner without changing the underlying DNA sequence.
In vascular endothelial cells, several specific downstream effects have been documented in research. Endothelin-1 (EDN1), a potent vasoconstrictor whose overexpression is associated with hypertension, atherosclerosis, and endothelial dysfunction, is normalized by Vesugen exposure in preclinical models.
Connexins, the gap junction proteins that allow endothelial cells to communicate electrically and chemically with each other, are restored. SIRT1, a sirtuin protein associated with metabolic regulation, insulin sensitivity, and cellular longevity, is upregulated. Ki-67 proliferation is stimulated in aging endothelial cells, supporting vascular tissue renewal.
A separate and important line of research involves Vesugen’s effects on the nervous system. Studies have found that the peptide modulates the expression of genes associated with neuronal differentiation (NES, GAP43), cell aging and apoptosis (p16, p21), and Alzheimer’s disease pathogenesis (SUMO, APOE, IGF1).
Research in models of Alzheimer’s disease showed Vesugen, along with related peptides such as Epitalon and Pinealon, restoring neuronal spine density and supporting neurogenesis markers.
The overlap between vascular and neurological effects is consistent with the known role of vascular health in cerebral blood flow and cognitive function.
Finally, research has linked Vesugen to SIRT1 activation in a broader metabolic context, with animal studies suggesting improvements in insulin sensitivity through this pathway, paralleling the effects observed with resveratrol.
This positions Vesugen as potentially relevant to metabolic health and age-related insulin resistance, though human evidence in this specific area is limited.
The research on Vesugen spans preclinical cell and animal models, small clinical studies in Russia, and broader bioregulator research from Khavinson’s group. Here is a breakdown by application area with the evidence characterized honestly for each one.
This is Vesugen’s primary and best-supported application. Research has demonstrated that the peptide stimulates endothelial cell proliferation, promotes the repair of vascular wall tissue, and normalizes key markers of endothelial dysfunction.
In in vitro and animal models, Vesugen exposure reduced endothelin-1 overexpression, restored gap junction communication between endothelial cells via connexin restoration, and increased SIRT1 activity.
These effects collectively support more resilient, functional vascular tissue, which matters particularly in the context of age-related endothelial decline and atherosclerosis.
One of the more clinically specific studies on Vesugen examined its use as a monotherapy in 41 patients with vasculogenic erectile dysfunction, which is ED caused by impaired penile arterial blood flow rather than hormonal or neurological factors.
Clinical and instrumental assessments including blood flow measurements in penile arteries were conducted before and after treatment. The results showed significant improvements in arterial blood flow, with both clinical outcomes and objective instrumental parameters improving following Vesugen administration.
The researchers concluded that Vesugen is an effective peptide bioregulator for improving vascular function in patients with atherosclerosis-related ED. This is one of the more methodologically specific studies in the Vesugen literature and provides direct clinical support for its vascular mechanism in a human population.
A 2017 study investigated Vesugen as a monotherapy in patients with chronic lower limb arterial insufficiency following surgical intervention. Atherosclerosis is responsible for the vast majority of lower limb chronic occlusive arterial disease, and the research posited that supplementation with endogenous vascular peptides could support vascular wall self-regulation in affected tissue.
The results showed therapeutic improvements in vascular function, consistent with the broader picture of Vesugen supporting peripheral circulation in compromised vascular beds.
Research on Vesugen’s neurological effects has expanded notably in recent years. Studies in models of Alzheimer’s disease showed Vesugen regulating the expression of genes associated with neuronal aging, apoptosis, and differentiation.
A 2021 study in the Bulletin of Experimental Biology and Medicine documented its effects on molecular-genetic aspects of neurogenesis regulation in Alzheimer’s disease models.
A related study found that Vesugen, alongside other Khavinson peptides, restored neuronal spine density (the connections between neurons that are progressively lost in neurodegenerative conditions) to normal levels.
A small Russian geriatric study also suggested that oral Vesugen combined with Pinealon improved cognitive and functional measures in workers exposed to harmful occupational conditions.
These findings are preliminary and require larger controlled replication, but the mechanistic rationale connecting vascular health, cerebral blood flow, and cognitive function gives them biological plausibility.
The official clinical indications for Vesugen in Russian medicine include atherosclerosis of the brain and lower limbs, coronary artery disease, hypertension, microcirculation disturbances, encephalopathy, and the consequences of ischemic attacks.
Clinical documentation from Russian practice describes Vesugen improving sleep and general wellbeing in patients with vascular and cardiac disorders, reducing cardiac arrhythmia, and normalizing blood pressure when used alongside antihypertensive medications, in some cases enabling dose reductions of conventional drugs.
These are clinical observations rather than controlled trial data, and they should be interpreted as such, but they are consistent with the mechanistic picture and represent decades of applied use in Russian medical practice.
Khavinson’s broader bioregulator program has consistently framed these peptides as geroprotectors: compounds that slow the functional decline associated with biological aging by restoring gene expression patterns toward more youthful states.
For Vesugen specifically, this is expressed through its effects on endothelial cell proliferation, Ki-67 gene activation in aging vascular tissue, SIRT1 upregulation, and the normalization of cellular communication via connexins.
Research has also documented Vesugen’s involvement in regulating prostatic fibroblast differentiation markers and enhancing CXCL12 expression, which is associated with stem cell homing and tissue repair.
These anti-aging mechanisms are among the more compelling aspects of the research, even if long-term human outcome data is not available.
Vesugen is available in three main delivery formats: oral capsules, sublingual drops, and injectable lyophilized powder. Each has a different dosing approach and practical considerations.
The standard oral dosing protocol from the St. Petersburg Institute is 1 to 2 capsules once or twice daily before meals, for a course of one month. Each capsule contains 10 mg of active synthesized peptides. T
he total daily dose therefore ranges from 10 to 40 mg depending on the protocol. After completing a course, a rest period of three to six months is recommended before repeating. For general wellness and proactive use from age 25 to 35, two courses per year is the standard guidance.
From age 40 to 50, biannual courses are recommended. After age 50, three courses per year is suggested. These recommendations are drawn from Khavinson’s clinical practice protocols rather than randomized controlled trial data, but they reflect decades of applied use in Russian medicine.
The sublingual form of Vesugen is administered as drops held under the tongue for 10 to 15 minutes before eating, which allows direct absorption through the oral mucosa and bypasses first-pass hepatic metabolism.
The recommended dose is 5 to 6 drops (0.25 to 0.35 mL) three to four times daily. One month of use is the standard course duration, with repetition after three to six months. The sublingual route is considered to offer better bioavailability than oral capsules for peptides that are susceptible to gastrointestinal degradation.
For research use, Vesugen is also available as a lyophilized powder for subcutaneous injection. A common reconstitution protocol is to add 3.0 mL of bacteriostatic water to a 20 mg vial, yielding a concentration of approximately 6.67 mg/mL.
The typical daily research range is 500 to 2,000 mcg once daily, with gradual titration upward. At 6.67 mg/mL, one unit on a U-100 insulin syringe equals approximately 66.7 mcg, making dosing straightforward with standard insulin syringes.
Lyophilized powder should be stored frozen at minus 20 degrees Celsius. After reconstitution, storage at 2 to 8 degrees Celsius and use within 30 days is recommended. Injection sites should be rotated across the abdomen, thighs, and upper arms to prevent local irritation.
Vesugen is commonly stacked with other Khavinson peptide bioregulators in Russian clinical practice. For cardiovascular and stress support, it is often combined with Ovagen (liver bioregulator) and Chonluten (lung bioregulator).
For cognitive and neurological support, Pinealon (brain bioregulator) is the most frequently mentioned companion. When running multiple bioregulators simultaneously, distributing their courses evenly throughout the year rather than running them all at the same time is the standard guidance from the St. Petersburg Institute.
After completing a Vesugen course, some protocols recommend transitioning to Ventfort, the natural extract version of the vascular bioregulator, for two additional months of continued support.
Vesugen’s safety profile is considered favorable based on the available research and its decades of use in Russian clinical practice.
As a short peptide derived from amino acid sequences naturally associated with vascular tissue, it does not carry the hormonal, hepatotoxic, or cardiovascular risks associated with anabolic compounds. It is non-hormonal and does not interact with androgen, estrogen, or corticosteroid pathways.
The most commonly reported side effects are mild and typically relate to the route of administration rather than the peptide itself.
For oral and sublingual use, minor digestive discomfort has been occasionally noted. For injectable use, local injection site irritation is the primary consideration, managed through site rotation and slow injection technique.
One theoretical caution worth noting is that Vesugen stimulates endothelial cell proliferation and supports cell renewal pathways. In individuals with active malignancy, any compound that promotes cellular proliferation requires careful consideration and medical supervision.
This is a general caution applicable to the bioregulator class rather than a documented adverse finding specific to Vesugen.
Vesugen is not recommended during pregnancy or breastfeeding, as no safety data exists for these populations. Drug interactions have not been formally characterized in Western clinical research.
In Russian practice, Vesugen has been used alongside antihypertensive medications without documented adverse interactions, and in some cases enabled dose reductions of those medications, but formal pharmacokinetic interaction studies are absent from the published literature.
The honest caveat that applies throughout is that the absence of large-scale Western clinical trials means the full safety profile, particularly for long-term or high-frequency use, has not been characterized by the standards that Western regulatory bodies require.
The available evidence points toward a favorable profile, but certainty is not the same as probability, and anyone with pre-existing cardiovascular or other serious conditions should involve a healthcare provider.
The most important thing to understand about Vesugen’s evidence base is where it comes from and what that means for how you should weight it.
The majority of research was produced by Khavinson’s group at the St. Petersburg Institute, and while the volume of publications is substantial (Khavinson is an author on over 775 scientific publications and 196 patents), much of it comes from a single research center and has not been independently replicated in Western laboratories.
The clinical studies that do exist are typically small in sample size, lack placebo controls in some cases, and have not been conducted under the randomized controlled trial methodology that FDA or EMA approval would require.
That does not make the research worthless. The mechanistic data on gene expression, endothelin-1 normalization, connexin restoration, and SIRT1 activation is published in peer-reviewed journals and is biochemically coherent.
The clinical study on vasculogenic ED used objective instrumental measurement of arterial blood flow, not just subjective reporting. The decades of clinical use in Russian medicine provide a real-world safety signal that no amount of preclinical data can replace.
What it does mean is that Vesugen sits in a different evidence category than compounds with large Western clinical trial programs behind them. It is a well-researched compound by the standards of the Russian bioregulator field, with a genuine scientific foundation and a favorable applied track record.
It is not validated by the same standard as an FDA-approved drug. For an informed adult making decisions about their own health, understanding that distinction clearly is more useful than either dismissing the research or overstating its certainty.
Vesugen occupies a genuinely interesting position in the peptide bioregulator space. It is not a newcomer riding a trend. It has 40 years of research behind it, approval for medical use in Russia, a mechanistically coherent mode of action involving gene expression regulation, and clinical data showing real improvements in vascular function in human patients.
The limitation is one of geography and methodology rather than biology. The research is real, but it has not yet crossed the threshold of large-scale Western validation.
For anyone already familiar with the bioregulator space and the Khavinson research program, Vesugen is one of the more scientifically credible compounds in the category. For anyone new to it, the right starting point is understanding the evidence honestly rather than filtering it through either skepticism or enthusiasm.
Vascular health is foundational. Endothelial function underpins blood pressure, circulation, cardiovascular disease risk, sexual health, and increasingly, cognitive function.
A compound with a credible mechanism, a real research record, and a decades-long clinical track record in those areas deserves serious consideration from anyone who takes a proactive approach to longevity and health optimization.
Frequently Asked Questions
Vesugen is primarily used to support vascular endothelial health, improve blood circulation, and address age-related decline in vascular function. In Russian medical practice it has been used for atherosclerosis, hypertension, coronary artery disease, peripheral arterial insufficiency, vasculogenic erectile dysfunction, and as a preventive geroprotector in aging individuals. It has also been studied for neuroprotection and cognitive support given the overlap between vascular health and brain function.
Each Khavinson peptide bioregulator is designed to target a specific organ or tissue system. Vesugen targets vascular endothelial cells specifically, whereas Epitalon targets the pineal gland and aging broadly, Pinealon targets the brain, Ovagen targets the liver, and Chonluten targets the lungs. The organ-specific targeting is built into the amino acid sequence and is what makes these compounds tissue-selective rather than general antioxidants or growth factors.
Vesugen works through gene expression changes that accumulate over the course of a cycle and beyond. Most users and clinical protocols suggest that meaningful effects on circulation and vascular function become apparent within the first one to two months of a course.
Effects from the bioregulator class are typically described as gradual and lasting, often extending months beyond the course itself as gene expression changes persist after the peptide is discontinued.
Based on available research and decades of Russian clinical use, Vesugen has a favorable safety profile. It is non-hormonal, non-toxic at standard doses, and has no documented significant interactions with most common medications based on available data.
The main gaps are the absence of large-scale Western controlled trials and formal pharmacokinetic interaction studies. It is not recommended during pregnancy, breastfeeding, or in individuals with active cancer. Anyone with serious pre-existing conditions should consult a healthcare provider before use.
Russian clinical practice documents Vesugen being used alongside antihypertensive medications, with some patients achieving blood pressure normalization at lower drug doses when Vesugen is added.
No adverse interactions have been documented in the published literature. However, because formal pharmacokinetic studies have not been conducted, anyone on cardiovascular medications should discuss Vesugen use with their prescribing physician before starting, and blood pressure monitoring during use is advisable.
DISCLAIMER: The information provided in this article is for educational and informational purposes only. Vesugen is not approved for human use by the FDA or any Western regulatory authority. It is approved for medical use in Russia and CIS countries. This content does not constitute medical advice. Always consult a qualified healthcare professional before using any research compound or peptide bioregulator, particularly if you have pre-existing health conditions or are taking prescription medications.
